The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Biomarkers for Homologous Recombination Deficiency in Cancer
Abstract
Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA repair pathway of clinical interest due to the sensitivity of homologous recombination-deficient cells to poly-ADP ribose polymerase (PARP) inhibitors. The measurement of homologous recombination deficiency (HRD) in cancer is therefore vital to the appropriate design of clinical trials incorporating PARP inhibitors. However, methods to identify HRD in tumors are varied and controversial. Understanding existing and new methods to measure HRD is important to their appropriate use in clinical trials and practice. The aim of this review is to summarize the biology and clinical validation of current methods to measure HRD, to aid decision-making for patient stratification and translational research in PARP inhibitor trials. We discuss the current clinical development of PARP inhibitors, along with established indicators for HRD such as germline BRCA1/2 mutation status and clinical response to platinum-based therapy. We then examine newer assays undergoing clinical validation, including 1) somatic mutations in homologous recombination genes, 2) "genomic scar" assays using array-based comparative genomic hybridization (aCGH), single nucleotide polymorphism (SNP) analysis or mutational signatures derived from next-generation sequencing, 3) transcriptional profiles of HRD, and 4) phenotypic or functional assays of protein expression and localization. We highlight the strengths and weaknesses of each of these assays, for consideration during the design of studies involving PARP inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [5]
In the citing paper
“In the clinic, germline BRCA1/2 mutation status is currently the main genetic biomarker of HRD5.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [5]
In the citing paper
“However, HRD rates in advanced metastatic cancer remain unclear, although these are the patients that are increasingly targeted with personalized treatments including PARP inhibitors for BRCA-deficiency5.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [5]
In the citing paper
“Genetic based detection of HRD in the clinic is commonly done by testing for pathogenic BRCA1/2 germline mutations5.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [5]
In the citing paper
“While somatic mutation testing improves diagnostic yield and is indeed increasingly performed in the clinic5, WGS based genetic testing is ultimately necessary to capture the full spectrum of genetic alterations and to accurately determine the mutational status of HR genes.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [5]
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“, is attributed to underlying HRD (73) and has been shown to exist in several cancers, including breast, ovarian, prostate, and gastric.”
BackgroundIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Cited by
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Pan-cancer landscape of homologous recombination deficiency.
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020) · Nature communications · doi:10.1038/s41467-020-19406-4 · Cited by 532
“While somatic mutation testing improves diagnostic yield and is indeed increasingly performed in the clinic[5], WGS based genetic testing is ultimately necessary to capture the full spectrum of genetic alterations and to accurately determine the mutational status of HR genes.”
BackgroundMethodInfluentialOvarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
The forefront of ovarian cancer therapy: update on PARP inhibitors
Mirza, M. R., Coleman, R. L., González-Martín, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.004 · Cited by 365
Metadata
- Authors
- Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D.
- Affiliations
- Cancer Science Institute of Singapore, National University Hospital, Singapore
- National University Hospital (SG)
- National University Cancer Institute, Singapore (SG)
- Corresponding author
- Tan, David S P
- Jeyasekharan, Anand D
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-18
- Volume
- 110
- Issue
- 7
- Pages
- 704-713
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2804007674
- Semantic Scholar
- 642f9229d63323879f018dabcea011e7b79fccd6
- Cited by
- 329
- References
- 116
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 35 · 2023: 49 · 2022: 69 · 2021: 57 · 2020: 47 · 2019: 11 · 2018: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Medical Research Council
- MOH Healthcare Research
- Cancer Science Institute
- Singapore Ministry of Health's National Medical Research Council (NMRC/CIRG/1400/2014)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- homologous recombination deficiency, PARP inhibitors, DNA repair deficiency, biomarkers, BRCA mutations, platinum sensitivity, mutational signatures, gene expression profiling, patient stratification, clinical trial design, homologous recombination genes
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Decision Support Techniques, DNA Repair, Genetic Testing, Humans, Neoplasms, Biomarkers, Tumor, Patient Selection, DNA Repair-Deficiency Disorders, Validation Studies as Topic, Homologous Recombination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers for Homologous Recombination Deficiency in Cancer. https://app.cochat.ai/papers/10.1093/jnci/djy085
- The paper
- Hoppe, M. M., Sundar, R., Tan, D. S. P., & Jeyasekharan, A. D. (2018). Biomarkers for Homologous Recombination Deficiency in Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.